Loading
New microscopes can measure dozens of proteins at once and map where immune cells sit in a tumour. These readouts could predict immunotherapy response, but every lab does it differently.
Multiplex immunofluorescence and spatial transcriptomics generate spatial biomarkers (immune cell distances, niches, tertiary lymphoid structures) with strong retrospective association to immunotherapy outcome. Platforms, panels, segmentation and metrics are not standardised, so no spatial biomarker has reached clinical validation. A consortium defining minimal reporting, reference tissue, shared segmentation benchmarks and a core panel would let spatial biomarkers be compared across studies and taken into prospective trials.
Shares 10x Genomics, Tumour-infiltrating lymphocytes (TILs), Single-cell & spatial profiling, Hot vs cold tumours.
Shares 10x Genomics, Tumour-infiltrating lymphocytes (TILs), Single-cell & spatial profiling, Hot vs cold tumours.
Shares 10x Genomics, Tumour-infiltrating lymphocytes (TILs), Single-cell & spatial profiling, Hot vs cold tumours.
Shares Single-cell & spatial profiling, Hot vs cold tumours, Digital pathology & AI, No one can predict who responds to immunotherapy.
Shares Tumour-infiltrating lymphocytes (TILs), Single-cell & spatial profiling, Hot vs cold tumours, No one can predict who responds to immunotherapy.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Digital pathology & AI, No one can predict who responds to immunotherapy, Biomarkers are not validated or standardised.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, No one can predict who responds to immunotherapy, Biomarkers are not validated or standardised.
Shares Tumour-infiltrating lymphocytes (TILs), Hot vs cold tumours, No one can predict who responds to immunotherapy.